ABSTRACT
OBJECTIVE: The aim of this study was to determine the response rate and toxicity of a 3-h paclitaxel infusion and carboplatin delivered as outpatient therapy for the treatment of stage III/IV epithelial ovarian cancer. METHODS: Thirty patients with stage III/IV epithelial ovarian cancer underwent cytoreductive surgery. The first 10 patients received adjuvant paclitaxel 150 mg/m2 via 3-h infusion on day 1 and carboplatin 5 times area under the curve on day 2 (group 1) every 28 days. The paclitaxel dose was escalated to 175 mg/m2 for the next 20 patients (group 2). chi 2 and Kaplan-Meier procedures were used for statistical analysis. RESULTS: Nine of 51 cycles in group 1 (17.6%) and 19 of 116 cycles (16.4%) in group 2 were associated with grade 4 neutropenia (P = 0.96), but only 2 of the 161 total cycles (0.01%) had fever and neutropenia. One patient in group 1 experienced grade 3 thrombocytopenia. Two patients in the entire group (7.4%) required colony-stimulating factors. One patient in group 2 (3.7%) had grade 3 neurotoxicity. With a median follow-up of 29 months for the entire group, 5 of 8 patients (62.5%) in group 1 and 14 of 19 patients (73.7%) in group 2 are alive. Median progression-free survival for group 1 and 2 is 13 and 14 months, respectively. Median overall survival has not been reached. CONCLUSIONS: Paclitaxel via 3-h infusion and carboplatin is an effective outpatient treatment for epithelial ovarian cancer that can be safely administered on schedule in the majority of patients.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Ovarian Neoplasms/drug therapy , Adult , Aged , Ambulatory Care , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carboplatin/administration & dosage , Carcinoma/pathology , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/pathology , Paclitaxel/administration & dosage , Treatment OutcomeABSTRACT
Although effeminacy is recognized to be a complex and important phenomenon, until now it has been only scantily studied, and has not been clearly defined or measured. In this paper, we review the literature and present an Effeminacy Rating Scale that quantifies the behavioral fragments comprising the overall clinical picture of effeminacy. We also present data obtained in a trial of the scale on a sample of 16 homosexual and 16 heterosexual males. The scale was found to have a high interrater reliability (0.93) and can therefore be used to study effeminacy quantitatively.
Subject(s)
Homosexuality/diagnosis , Paraphilic Disorders/diagnosis , Personality Inventory , Adult , Humans , Interview, Psychological , Male , Middle AgedABSTRACT
In Part II, effeminacy in an in vivo social situation was studied and the Effeminacy Scale described in Part I was tested. Nineteen subjects were studied and videotaped while participating in four encounter groups, of which two were homosexual and two heterosexual. There were large situational variations in expressivity of effeminacy during group meetings. High-frequency levels of effeminate responses were observed to parallel high levels of anxiety or anger. At other times, effeminate responses were observed which seemed to subserve sexual signaling functions or which seemed related to narcissistic retreat (self-cuddling) or castration anxiety (e.g., cupping the genitals). Interrater reliability with the Effeminacy Scale for two nonprofessional raters viewing the same videotaped material from the group was 0.93 (Pearson r).
